|Bid||38.7000 x 500|
|Ask||39.3000 x 100|
|Day's Range||35.3901 - 40.9999|
|52 Week Range||5.0000 - 51.9000|
|PE Ratio (TTM)||14.27|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||42.67|
SANTA MONICA, Calif., Sept. 25, 2017-- Opiant Pharmaceuticals, Inc.,, today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on ...
Opiant Pharmaceuticals jumped nearly 30% yesterday on a favorable report from Zacks, making it the forth largest position in Todd Hagopian's Biotech Fund. Here's what Todd thinks of the news.
On December 15, 2016, Opiant Pharmaceuticals, Inc. (OPNT) announced an agreement with SWK Holdings Corporation whereby SWK acquired the rights to certain royalty and milestone payments related to the sale of NARCAN® Nasal Spray for an initial payment of $13.7 million and the potential for an additional $3.75 million if certain future net sales milestones are met. On August 10, 2017, Opiant announced an additional $3.75 million payment from SWK related to the royalty monetization agreement related to the sale of NARCAN® Nasal Spray signed between Opiant and SWK in December 2016. According to the agreement, the $3.75 million payment was due to Opiant upon Adapt Pharma recording $25 million in cumulative net sales of NARCAN® Nasal Spray for any two consecutive quarters from Oct. 1, 2016 to Sep. 30, 2017.